Immune to Cancer: The CRI Blog
-
Hiking the Appalachian Trail for Cancer Research: A Q&A with Dan Harris
As a survivor of two bouts of cancer—testicular and lung—and having lost friends to the disease, Dan…
-
Our Supporters #WearWhite for a Future Immune to Cancer
On June 15, hundreds of scientists, patients, advocates, and healthcare professionals donned white apparel for our sixth…
-
30 Days of CRI Impact: Understanding Immune Checkpoints and Pathways
This week’s CRI breakthroughs deal with the development of checkpoint immunotherapy and other advances that have helped…
-
First Checkpoint Immunotherapy Approved for Advanced Cervical Cancer
Pembrolizumab, a PD-1-targeting immunotherapy, was approved for recurrent advanced cervical cancer that expresses PD-L1.
-
30 Days of CRI Impact: Laying the Foundation for Cancer Immunotherapy
The first nine days in June 2018 highlight early discoveries that helped establish cancer immunotherapy's foundations.
-
ASCO18 Recap: How Immunotherapy is Revolutionizing Cancer Treatment
Our recap of the immunotherapy highlights from the world’s largest clinical cancer conference in 2018
-
What Cancer Patients Should Know: Latest Immunotherapy News from ASCO 2018
Drs. Charles G. Drake, Catherine Diefenbach, and Jeffrey S. Weber discuss the latest cancer immunotherapy advances out of the 2018 ASCO annual meeting.
-
ASCO18 Update: Using Biomarkers to Improve Immunotherapy
The final day of ASCO18 focused on biomarkers’ potential to improve immunotherapy as well as the next-generation…
-
ASCO18 Update: Much Ado About Melanoma (and Lung Cancer, Too)
Day 4 of ASCO18 focused on the past, present, and future of melanoma treatment, and also revealed…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.